$CUE
Cue Biopharma Inc

2018 Q3 Form 10-Q Financial Statement

#000156459018029316 Filed on November 13, 2018

View on sec.gov

Income Statement

Concept 2018 Q3 2017 Q4 2017 Q3
Revenue $449.0K $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.890M $1.410M $1.030M
YoY Change 180.58% 80.77% 66.13%
% of Gross Profit
Research & Development $10.31M $8.900M $3.880M
YoY Change 165.8% 345.0% 189.55%
% of Gross Profit
Depreciation & Amortization $195.0K $130.0K $120.0K
YoY Change 62.5% 116.67% 100.0%
% of Gross Profit
Operating Expenses $10.31M $10.44M $5.032M
YoY Change 104.95% 267.61% 149.11%
Operating Profit -$12.76M -$5.032M
YoY Change 153.56%
Interest Expense $102.0K $0.00 $0.00
YoY Change
% of Operating Profit
Other Income/Expense, Net $200.0K
YoY Change
Pretax Income -$12.56M -$10.44M -$5.030M
YoY Change 149.68% 267.61% 149.01%
Income Tax $0.00
% Of Pretax Income
Net Earnings -$12.55M -$10.44M -$5.032M
YoY Change 149.42% 267.61% 149.11%
Net Earnings / Revenue -2795.32%
Basic Earnings Per Share
Diluted Earnings Per Share -$623.9K -$627.4K -$302.3K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2018 Q3 2017 Q4 2017 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $39.20M $63.53M $3.400M
YoY Change 1052.94%
Cash & Equivalents $16.04M $63.53M $3.400M
Short-Term Investments $23.40M $0.00 $0.00
Other Short-Term Assets $1.400M $1.500M $600.0K
YoY Change 133.33%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $40.60M $65.07M $4.100M
YoY Change 890.24%
LONG-TERM ASSETS
Property, Plant & Equipment $2.900M $1.691M $1.700M
YoY Change 70.59%
Goodwill
YoY Change
Intangibles $175.0K $175.0K
YoY Change
Long-Term Investments
YoY Change
Other Assets $900.0K $198.3K $200.0K
YoY Change 350.0%
Total Long-Term Assets $3.982M $1.889M $2.200M
YoY Change 81.0%
TOTAL ASSETS
Total Short-Term Assets $40.60M $65.07M $4.100M
Total Long-Term Assets $3.982M $1.889M $2.200M
Total Assets $44.58M $66.95M $6.300M
YoY Change 607.65%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $997.0K $1.659M $800.0K
YoY Change 24.63%
Accrued Expenses $2.268M $1.151M $900.0K
YoY Change 152.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.585M $5.347M $1.900M
YoY Change 141.32%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $0.00
YoY Change
Total Long-Term Liabilities $0.00 $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $4.585M $5.347M $1.900M
Total Long-Term Liabilities $0.00 $0.00 $0.00
Total Liabilities $5.178M $5.347M $1.900M
YoY Change 172.53%
SHAREHOLDERS EQUITY
Retained Earnings -$60.18M -$32.82M
YoY Change
Common Stock $99.60M $94.43M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $39.40M $61.61M $4.400M
YoY Change
Total Liabilities & Shareholders Equity $44.58M $66.95M $6.300M
YoY Change 607.65%

Cashflow Statement

Concept 2018 Q3 2017 Q4 2017 Q3
OPERATING ACTIVITIES
Net Income -$12.55M -$10.44M -$5.032M
YoY Change 149.42% 267.61% 149.11%
Depreciation, Depletion And Amortization $195.0K $130.0K $120.0K
YoY Change 62.5% 116.67% 100.0%
Cash From Operating Activities -$6.290M -$1.890M -$3.680M
YoY Change 70.92% -5.97% 137.42%
INVESTING ACTIVITIES
Capital Expenditures -$300.0K -$10.00K -$210.0K
YoY Change 42.86% -90.0% -19.23%
Acquisitions
YoY Change
Other Investing Activities -$23.31M $0.00
YoY Change
Cash From Investing Activities -$23.61M -$10.00K -$210.0K
YoY Change 11142.86% -90.0% -19.23%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 10.00K 62.04M -20.00K
YoY Change -150.0% 313.05% 100.0%
NET CHANGE
Cash From Operating Activities -6.290M -1.890M -3.680M
Cash From Investing Activities -23.61M -10.00K -210.0K
Cash From Financing Activities 10.00K 62.04M -20.00K
Net Change In Cash -29.89M 60.14M -3.910M
YoY Change 664.45% 365.84% 114.84%
FREE CASH FLOW
Cash From Operating Activities -$6.290M -$1.890M -$3.680M
Capital Expenditures -$300.0K -$10.00K -$210.0K
Free Cash Flow -$5.990M -$1.880M -$3.470M
YoY Change 72.62% -1.57% 168.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2018Q3 us-gaap Assets
Assets
44582000
CY2018Q3 us-gaap Preferred Stock Value
PreferredStockValue
CY2017Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2018Q3 us-gaap Common Stock Value
CommonStockValue
20000
CY2018Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2018Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12579000
CY2017Q4 us-gaap Deposits Assets Current
DepositsAssetsCurrent
225000
CY2018Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1380000
us-gaap Operating Income Loss
OperatingIncomeLoss
-27730000
us-gaap Operating Income Loss
OperatingIncomeLoss
-12795000
CY2018Q3 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
102000
us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
272000
CY2018Q3 us-gaap Liabilities Current
LiabilitiesCurrent
4585000
CY2017Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5347000
CY2018Q3 cue Research And Development Contract Liability Noncurrent
ResearchAndDevelopmentContractLiabilityNoncurrent
593000
CY2018Q3 us-gaap Liabilities
Liabilities
5178000
CY2017Q4 us-gaap Liabilities
Liabilities
5347000
CY2017Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
36000
CY2018Q3 us-gaap Deposit Assets
DepositAssets
777000
CY2018Q3 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
175000
CY2017Q4 us-gaap Indefinite Lived Trademarks
IndefiniteLivedTrademarks
175000
CY2017Q4 cue Long Term Service Contract Noncurrent
LongTermServiceContractNoncurrent
23000
CY2017Q4 us-gaap Assets
Assets
66954000
CY2018Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
997000
CY2017Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1660000
CY2018Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2268000
CY2017Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1151000
CY2018Q3 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
1095000
CY2017Q4 cue Research And Development Contract Liability Current
ResearchAndDevelopmentContractLiabilityCurrent
2500000
CY2018Q3 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
225000
CY2017Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
94408000
CY2018Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-20000
CY2018Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-60180000
CY2017Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-32821000
CY2018Q3 us-gaap Stockholders Equity
StockholdersEquity
39404000
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
61607000
CY2017Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
66954000
CY2017Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2017Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2017Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2017Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2017Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2017Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19459194
CY2017Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19459194
CY2018Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
449000
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
812000
CY2018Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2895000
CY2017Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1030000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
6821000
CY2018Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
10313000
us-gaap Operating Expenses
OperatingExpenses
12795000
CY2017Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5032000
CY2018Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
98000
CY2017Q4 us-gaap Common Stock Value
CommonStockValue
19000
CY2017Q4 cue Common Stock To Be Issued
CommonStockToBeIssued
1000
CY2018Q3 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
99584000
CY2018Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
44582000
CY2018Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2018Q3 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2018Q3 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2018Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2018Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
50000000
CY2018Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
20133266
CY2018Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
20133266
us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
9881000
CY2017Q3 us-gaap Operating Expenses
OperatingExpenses
5032000
us-gaap Operating Expenses
OperatingExpenses
28542000
CY2018Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-12759000
CY2018Q3 us-gaap Net Income Loss
NetIncomeLoss
-12559000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
371000
CY2017Q3 us-gaap Net Income Loss
NetIncomeLoss
-5032000
us-gaap Net Income Loss
NetIncomeLoss
-27359000
us-gaap Net Income Loss
NetIncomeLoss
-12795000
CY2018Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.62
CY2017Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.47
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.36
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
99000
CY2018Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
200000
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10635684
CY2018Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-20000
us-gaap Profit Loss
ProfitLoss
-27359000
us-gaap Profit Loss
ProfitLoss
-12795000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
-20000
CY2018Q3 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-20000
us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-20000
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.20
CY2018Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20132277
CY2017Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
10635684
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
20111519
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12795000
CY2018Q3 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
0
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1186000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
157000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-22513000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10296000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1734000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1011000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
23307000
us-gaap Payments To Acquire Intangible Assets
PaymentsToAcquireIntangibleAssets
175000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-25041000
us-gaap Depreciation
Depreciation
556000
us-gaap Depreciation
Depreciation
293000
us-gaap Share Based Compensation
ShareBasedCompensation
5163000
us-gaap Share Based Compensation
ShareBasedCompensation
2001000
cue Deferred Rent
DeferredRent
-188000
cue Deferred Rent
DeferredRent
82000
cue Premium Paid On Securities Purchased
PremiumPaidOnSecuritiesPurchased
52000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
101000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
300000
us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
-551000
us-gaap Increase Decrease In Deposits
IncreaseDecreaseInDeposits
-109000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-662000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
222000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1117000
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
317000
cue Increase Decrease In Research And Development Contract Liability
IncreaseDecreaseInResearchAndDevelopmentContractLiability
-812000
cue Payments Of Deferred Public Offering Costs
PaymentsOfDeferredPublicOfferingCosts
44000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
12000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-44000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-47542000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-11526000
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
63584000
CY2016Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
14976000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
16042000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
3450000
cue Accrual Of Deferred Offering Costs
AccrualOfDeferredOfferingCosts
197000
us-gaap Prior Period Reclassification Adjustment Description
PriorPeriodReclassificationAdjustmentDescription
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Reclassification</p> <p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Certain amounts previously reported in current liabilities for the prior period have been reclassified to the current period presentation to segregate accounts payable and accrued liabilities to conform with current period presentation.&nbsp;&nbsp;Also, certain amounts previously reported in research and development contract advances have been reclassified to the current period presentation to combine research and development contract advances and prepaid expenses.&nbsp;&nbsp;In addition, certain amounts previously reported as reductions to research and development expenses have been reclassified to collaboration revenue to conform with current period presentation.&nbsp;&nbsp;There was no impact to reported net loss.&nbsp;&nbsp;The reclassifications did not have a material impact on previously reported financial statements.</p></div>
us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenue and expense during the reporting period. Significant estimates include the accounting for revenue recognition, collaboration agreements, potential liabilities, the assumptions utilized in valuing stock-based compensation issued for services, the realization of deferred tax assets, and the impairment of long-lived assets and intangibles. Actual results could differ from those estimates. </p></div>
us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Risks and Uncertainties </p> <p style="margin-top:6pt;margin-bottom:0pt;color:#000000;letter-spacing:-0.1pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company&#8217;s operations are subject to a number of factors that may affect its operating results and financial condition. Such factors include, but are not limited to: the Company&#8217;s ability to determine candidates for clinical testing, the results of clinical testing and trial activities of the Company&#8217;s product candidates, the Company&#8217;s ability to obtain regulatory approval to market its product candidates, the Company&#8217;s intellectual property, competition from products manufactured and sold or being developed by other companies, the price of, and demand for, the Company&#8217;s product candidates if approved for sale, the Company&#8217;s ability to negotiate favorable licensing or other manufacturing and marketing agreements for its product candidates, and the Company&#8217;s ability to raise capital. </p> <p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company currently has no commercially approved product candidates and there can be no assurance that the Company&#8217;s research and development programs will be successfully commercialized. Developing and commercializing a product requires significant time and capital and is subject to regulatory review and approval, as well as competition from other biotechnology and pharmaceutical companies. The Company operates in an environment of rapid change and is dependent upon the continued services of its employees and consultants and obtaining and protecting its intellectual property. </p></div>
CY2018Q3 us-gaap Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
23359000
CY2018Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
16042000
CY2017Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3450000
dei Entity Incorporation State Country Name
EntityIncorporationStateCountryName
Delaware
dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2014-12-31
CY2018Q3 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
39181000
cue Number Of Commercial Approved Product Candidates
NumberOfCommercialApprovedProductCandidates
0
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5680262000
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
2736591000
CY2017Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
3400000
CY2017Q3 us-gaap Restricted Cash Current
RestrictedCashCurrent
50000
CY2018Q3 us-gaap Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
20000
CY2018Q3 us-gaap Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
23339000
CY2017Q3 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
0
CY2018Q3 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
4031000
CY2017Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
2352000
CY2018Q3 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
1162000
CY2017Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
661000
us-gaap Property Plant And Equipment Disposals
PropertyPlantAndEquipmentDisposals
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.0243
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.0292
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.820
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.836
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2732221
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1705600
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
2500
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
7500
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
4427821
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1192953
CY2017Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
4.07
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
11.88
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
7.08
CY2018Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
3.85
CY2017 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y9M3D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P5Y7M24D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P4Y8M19D
CY2018Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
17488000
CY2018Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
6208000
CY2018Q3 cue Share Based Compensation Arrangement By Share Based Payment Award Fair Value Of Options Exercisable Intrinsic Fair Value Per Share
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueOfOptionsExercisableIntrinsicFairValuePerShare
9.05
CY2018Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2730000
CY2017Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
751000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
5163000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2001000
cue Number Of Tranches
NumberOfTranches
2
CY2018Q3 us-gaap Revenue Remaining Performance Obligation
RevenueRemainingPerformanceObligation
2500000
us-gaap Description Of Lessee Leasing Arrangements Operating Leases
DescriptionOfLesseeLeasingArrangementsOperatingLeases
Upon execution of this lease agreement the Company prepaid three months of rent, two of which will be held in escrow and credited against future rent payments and one month that was applied to the first months rent. The Company also prepaid seven and one half months rent pursuant to an amendment to the lease agreement executed on June 18, 2018. These amounts were recorded to deposits and prepaid expenses, respectively at September 30, 2018.
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Remainder Of Fiscal Year
OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear
904000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
4461000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
4911000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
1432000
CY2018Q3 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
11708000
CY2018Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
863000
CY2017Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
505000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2250000
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
1471000
cue Additional Description Of Lessee Leasing Arrangements Operating Leases
AdditionalDescriptionOfLesseeLeasingArrangementsOperatingLeases
Upon execution of this lease agreement the Company prepaid three months of rent which will be held in escrow and credited against future rent payments. The Company also prepaid twelve months rent pursuant to the lease agreement executed on September 20, 2018. These amounts were recorded to deposits and prepaid expenses, respectively at September 30, 2018.

Files In Submission

Name View Source Status
0001564590-18-029316-index-headers.html Edgar Link pending
0001564590-18-029316-index.html Edgar Link pending
0001564590-18-029316.txt Edgar Link pending
0001564590-18-029316-xbrl.zip Edgar Link pending
cue-10q_20180930.htm Edgar Link pending
cue-20180930.xml Edgar Link completed
cue-20180930.xsd Edgar Link pending
cue-20180930_cal.xml Edgar Link unprocessable
cue-20180930_def.xml Edgar Link unprocessable
cue-20180930_lab.xml Edgar Link unprocessable
cue-20180930_pre.xml Edgar Link unprocessable
cue-ex311_10.htm Edgar Link pending
cue-ex312_6.htm Edgar Link pending
cue-ex321_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gxt2prdv00k4000001.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending